Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
Condition(s):Lymphoproliferative DisorderLast Updated:December 19, 2013Unknown status
Hide Studies Not Open or Pending
Condition(s):Lymphoproliferative DisorderLast Updated:December 19, 2013Unknown status
Condition(s):Lymphoproliferative DisorderLast Updated:August 6, 2019Completed
Condition(s):Relapsed or Refractory Chronic Lymphoproliferative DisordersLast Updated:October 21, 2010Completed
Condition(s):Post-transplant Lymphoproliferative Disorder; PTLDLast Updated:March 22, 2017Withdrawn
Condition(s):Posttransplant Lymphoproliferative DisorderLast Updated:August 25, 2022Completed
Condition(s):Lymphoproliferative DisorderLast Updated:April 25, 2023Terminated
Condition(s):Leukemia; Lymphoproliferative DisordersLast Updated:April 15, 2013Withdrawn
Condition(s):Indolent Lymphoproliferative DisordersLast Updated:June 16, 2016Unknown status
Condition(s):Post-transplantation Lymphoproliferative DisordersLast Updated:December 6, 2016Completed
Condition(s):Lymphoid Malignancies; Lymphoproliferative DisordersLast Updated:August 1, 2011Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.